New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 3 # 4 August 1997
State-of the-Art in the Management of Cancer

Head and Neck Cancer-Part I
Epidemiology, etiology and Molecular Markers

Epidemiology

International Epidemiology

  • Incidence of head and neck cancer
  • Mortality associated with head and neck cancer

USA Epidemiology

Etiology and Risk Factors

Oral Cancer

Nasopharyngeal Cancer

Molecular Markers

Oncogenes and Tumor Suppressor Genes

Growth Factors

Matrix Metalloproteinases

Other Molecular Factors

Molecular Epidemiology

Anti-cancer Drug Development

Taxanes-PART I

Status of TAxANES and The Outlook for

GENERIC versions of paclitaxel

Clinical Issues

Taxol

Taxotere

Paxene

Taxol Patent and Exclusivity Issues

Approved/Marketed Generic Versions of Paclitaxel

Suppliers of Paclitaxel to Drug Companies

  • Hauser
  • Indena
  • NaPro BioTherapeutics

Marketers of Generic Paclitaxel

  • Dabur
  • F. H. Faulding
  • Immunex
  • Yew Tree Pharmaceuticals

Meeting Coverage

NEW APPROACHES IN THE TREATMENT OF GASTROINTESTINAL CANCERS

From the 33rd Annual Meeting of the American Society of Clinical Oncology

Denver, Colorado, May 17-20, 1997

Gastric Cancer

Monotherapy

  • Docetaxel
  • Paclitaxel

Combination Therapies

Hepatocellular Carcinoma

Multimodality Therapy

  • Liver transplantation combined with neoadjuvant and adjuvant chemotherapy

Intra-arterial Lipodol-iodine 131

Pancreatic Cancer

  • PNU-214565

Colorectal Cancer

Monotherapy

  • AG-337
  • Raltitrexed
  • Irinotecan
  • Capecitabine

Combination Regimens

5-FU Administration Options

Multimodality Therapy

  • Chemoradiation

Carcinoid Syndrome

Octreotide Acetate LAR


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887